

Date: 30th October, 2017

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd
'Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2017.

Further, we enclose herewith Limited Review Report by Statutory Auditors on Unaudited Financial Results for the quarter and half year ended 30th September, 2017.

The time of commencement of the Board Meeting was 12:00 noon and the time of conclusion was 01:25 p.m.

We request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For Alembic Limited



Drigesh Mittal
Company Secretary

Encl.: as above

ALEMBIC LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2017

	Particulars	Quarter Ended			Half Year Ended		Rs. in Lacs
		30-09-2017 (Unaudited)	30-06-2017 (Unaudited)	30-09-2016 (Unaudited)	30-09-2017 (Unaudited)	30-09-2016 (Unaudited)	31-03-2017 (Audited)
1	Revenue from operations	3,254	2,961	5,162	6,215	8,438	14,427
2	Other Income	2,597	385	2,497	2,983	2,648	3,097
3	Total Income	5,852	3,346	7,659	9,198	11,086	17,524
4	Expenses						
	Cost of Materials Consumed	1,126	619	1,539	1,745	2,824	5,097
	Cost of Construction	769	641	2,485	1,410	3,053	4,730
	Changes in Inventories of Finished Goods and WIP	154	746	(533)	899	(494)	(882)
	Employee Benefit Expenses	515	493	694	1,008	1,370	2,284
	Finance Costs	7	4	6	11	12	16
	Depreciation and amortisation expense	112	123	125	236	254	509
	Other expenses	192	285	646	477	1,233	2,525
	Total Expenses	2,875	2,911	4,962	5,786	8,252	14,279
5	Profit Before Exceptional Items and Tax	2,976	435	2,696	3,412	2,833	3,245
6	Exceptional items - Voluntary settlement payment	-	-	576	-	576	581
7	Profit before Tax	2,976	435	2,120	3,412	2,257	2,664
8	Tax expenses						
	1 Current Tax (MAT)	137	90	(11)	227	3	39
	2 Deferred Tax	17	11	(130)	28	(145)	(125)
9	Net Profit for the Period	2,822	335	2,261	3,157	2,399	2,750
10	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	521	5	(523)	526	162	(372)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(180)	(3)	180	(183)	(50)	86
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	(78)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	26
11	Total Comprehensive Income for the period	3,163	337	1,917	3,500	2,511	2,411
12	Earning per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	1.06	0.13	0.85	1.18	0.90	1.03



ALEMBIC LIMITED
SEGMENT WISE REVENUE AND RESULTS

Particulars	Quarter Ended			Half Year Ended		Rs. in Lacs
	30-09-2017	30-06-2017	30-09-2016	30-09-2017	30-09-2016	Year Ended
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Segment Revenue						
Revenue from operations						
a. Active Pharmaceutical Ingredients Business	1,776	1,743	1,738	3,519	3,835	7,017
b. Real Estate Business	1,479	1,218	3,424	2,696	4,603	7,410
Total Income from Operations (Net)	3,254	2,961	5,162	6,215	8,438	14,427
2 Segment Results (Profit(+)/ Loss(-) before Taxes and interest from each segment)						
a. Active Pharmaceutical Ingredients Business	139	5	(253)	144	(367)	(594)
b. Real Estate Business	354	163	555	517	731	1,148
Total	494	168	302	661	364	555
Less: Unallocable Income and Expenditure						
(i) Interest Expense	7	4	6	11	12	16
(ii) Exceptional items -Active Pharmaceutical Ingredients Business	-	-	576	-	576	581
(iii) Dividend Income & loss/(gain) on financial asset at Fair Value	(2,503)	(235)	(2,365)	(2,738)	(2,446)	(2,487)
(iv) Other Expense/ (Income)	13	(37)	(36)	(24)	(36)	(218)
Total Profit before Tax	2,976	435	2,120	3,412	2,257	2,663
3 Segment Assets						
a. Active Pharma Ingredients Business	18,887	19,627	22,687	18,887	22,687	19,328
b. Real Estate Business	7,295	6,778	5,918	7,295	5,918	6,571
c. Unallocated	21,338	19,453	17,847	21,338	17,847	18,967
Total	47,520	45,858	46,452	47,520	46,452	44,866
4 Segment Liabilities						
a. Active Pharma Ingredients Business	2,180	3,139	4,626	2,180	4,626	2,650
b. Real Estate Business	4,195	4,368	3,732	4,195	3,732	4,260
c. Unallocated	1,512	1,242	2,483	1,512	2,483	1,185
Total	7,887	8,749	10,841	7,887	10,841	8,095

Notes :

- The above results have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- Revenue from Operations for the current quarter are not comparable with previous periods, since sales for the current quarter are net of Goods and Services Tax (GST), whereas, Excise Duty formed part of the same and other expenses in the previous periods.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 30th October, 2017



For Alembic Limited

Chirayu Amin
Chairman

Alembic Limited

Statement of Assets and Liabilities

Rs. in Lacs

Particulars	As at 30th September, 2017	As at 31st March, 2017
	(Unaudited)	(Audited)
ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipment	14,001	14,760
(b) Capital Work-in-Progress	50	16
(c) Investment Property	3,143	2,381
(d) Financial Assets		
(i) Investments	8,919	8,376
(ii) Loans	25	22
(iii) Others	119	115
(e) Other non-current assets	-	69
Current assets		
(a) Inventories	4,315	5,061
(b) Financial Assets		
(i) Investments	12,300	10,476
(ii) Trade Receivables	2,478	2,160
(iii) Cash and cash equivalents	309	192
(iv) Bank balances other than (iii) above	38	39
(v) Loans	4	-
(vi) Others	1	20
(c) Other Current Assets	1,618	1,178
(d) Assets held for sale	200	-
Total Assets	47,520	44,866
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	5,341	5,341
(b) Other Equity	34,292	31,431
LIABILITIES		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Others financial liabilities	198	178
(b) Provisions	80	78
(c) Deferred Tax Liability (net)	1,218	1,005
Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	1,623	1,476
(ii) Others financial liabilities	1,123	1,069
(b) Other current liabilities	2,286	2,851
(c) Provisions	1,065	1,258
(d) Current Tax Liabilities (net)	294	180
Total Equity and Liabilities	47,520	44,866

Place : Vadodara

Date : 30th October, 2017



For Alembic Limited

Chirayu Amin
Chairman

Limited Review Report**To the Board of Directors of Alembic Limited**

1. We have reviewed the accompanying statement of unaudited standalone Ind-AS financial results of **Alembic Limited** ("the Company") for the quarter/half year ended 30th September, 2017 ("the Statement") together with the notes thereon attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No CIR/CFD/FAC/62/2016 dated 5th July, 2016 which has been initialed by us for identification purposes.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Ind-AS financial results prepared in accordance with applicable Indian Accounting Standards, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **C N K & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W-100036

**Himanshu Kishnadwala**

Partner

Membership No.37391

Place: Vadodara

Date: 30th October, 2017